About the Founder

During the past ten years, Dr. Parham Jabbarzadeh Kaboli, a dedicated researcher with an h-Index of 22, has charted an impressive academic journey in cancer pharmacology, pharmacogenomics, and drug discovery. Beginning with a strong foundation in herbal medicine, he earned his PhD in Pharmacology from the prestigious University Putra Malaysia. Under the guidance of mentors like Dr. King-Hwa Ling and Professor Johnson Stanslas, Parham transitioned to the multifaceted disciplines of Pharmacology and Toxicology, significantly impacting his academic trajectory. His contributions to breast cancer research include groundbreaking work on c-MET receptor tyrosine kinase and galectin-9 signaling pathways. Parham's current postdoctoral research at China Medical University in Taiwan, mentored by President Mien-Chie Hung, continues to drive advancements in cancer biology and treatment. His journey exemplifies international collaboration and dedication to scientific exploration.

Research Spotlight

Triple-negative breast cancer (TNBC) is challenging, making up 15–20% of all breast cancer cases. This study examined how certain drugs, like lapatinib (a dual tyrosine kinase inhibitor targeting EGFR and Her2) and berberine (a plant-based compound), affect TNBC cells. We found that lapatinib activates a protein called Akt in MDA-MB231 TNBC cells, which could contribute to the cancer's resistance to treatment. We also studied the genetic profiles of different TNBC cell lines and patients. Interestingly, lapatinib and berberine enhanced Akt activity in TNBC cells, making them more resistant to treatment. These findings suggest that these drugs may not be effective in treating TNBC and could even make the cancer more resistant to therapy.

Our recent research analyzed the gene expression of specific cancer-promoting proteins in ten different triple-negative breast cancer (TNBC) cell lines and TNBC patients, utilizing GEO and TCGA databases. Our current findings have highlighted that the majority of the chosen cell lines, including MDA-MB231 and TNBC patients, exhibit decreased levels of AKT1, PIK3CA, PTEN, and EGFR genes while showing increased levels of KRAS and DNMTs. These observations suggest that these genes are associated with the invasive nature of TNBC.

Global Collaborations

The Cancer Discovery Network emerges as a dynamic crucible, uniting dedicated academics and passionate researchers in a collective pursuit of driving innovation in cancer research. With a resolute mission to cultivate novel ideas and channel them into impactful publications, the network serves as a beacon of collaboration, aiming to reshape the landscape of cancer understanding and treatment.

A Collaborative Ecosystem

The essence of Cancer Discovery Network lies in its ability to foster collaboration across diverse echelons of expertise. The network offers a meticulously structured membership framework that accommodates different roles:

Faculty Membership
Student Membership
Premium Membership

Join Now

Publication Excellence

The culmination of Cancer Discovery Network's collaborative endeavors lies in publication. The network offers members a unique opportunity to channel their research outcomes into high-impact Q1 journals. This validates the network's commitment to excellence and amplifies the reach of its discoveries, influencing a broader scientific community.

Research Impact

Impact Factor

h-Index

Citations

Testimonials

Working with Dr. Parham Jabbarzadeh is one of my best experiences. Not only I've learned beside him, but also my view about research has changed due to his inspirational spirit. His method of research is problem-oriented, which advances the path with teamwork in a meticulous and planned manner. He knows how to lead a team and evoke them to think out of the box to create novel ideas.

Ghazaal Roozitalab B.Sc. in Nurse Anesthesia

Dr. Parham, You are an extremely literate, experienced and responsible person who made us more enthusiastic about science and research with a broad view of science. I am extremely pleased that I have had experience of working with you.

Behnaz Abedi M.Sc in Clinical Biochemistry

The energetic approach of Dr. Parham Jabbarzadeh Kaboli, a unique authority on cancer biology, demonstrates his enthusiasm and commitment to the subject. He has continuously shown a remarkable capacity to delve into the most intricate facets of cancer biology with his dynamic and hyperactive approach to research. The professional life of Dr. Parham is embellished with a brilliant personality that exudes passion and dedication in his job. His multidisciplinary approach has produced ground-breaking findings about the anti-cancer effects of berberine, showcasing his extraordinary abilities and leadership.

Masoumeh Jomhori M.Sc. in Biotechnology

Mahdieh Emadi M.Sc. in Biophysics

I am very happy to be a member of Dr. Parham Jabbarzadeh's team. I started my research in the field of cancer for the first time with Dr. Parham and it was one of the best and most professional experiences in my academic life because he is very polite and very professional in his work. In fact, one of the best features of Dr. Parham is his abundant positive energy, which makes me work completely without stress, and interacting with him is very enjoyable and full of peace. Good luck to dear Dr. Parham and all members of his academy.

Mojgan Fathinejad M.Sc. in Biochemistry

It's been less than a year since I met Dr.Parham Jabbarzadeh Kaboli through LinkedIn. I had the opportunity to collaborate on a review article with his team. In my view, the greatest strengths of his work are hist strict follow-up, excellent training, work mastery and excellent knowledge in the field of cancer.

Rahil Ghanbarnasab M.Sc. in Medical Physics

New Discovery

c-MET, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that plays a crucial role in various solid tumors like lung, breast, and liver cancers. Recent single-cell analysis has revealed that c-MET significantly impacts the composition of immune cells within the tumor microenvironment. It promotes an immunosuppressive environment by transforming anti-cancer M1 macrophages into tumorigenic M2 macrophages and converting CD4+Th cells into Treg cells by upregulating PD-L1, TGF-β, and IL-10. Our current research explores the potential of targeting c-MET as an immunotherapeutic strategy.

Traditionally, c-MET was known to have a single ligand, HGF. However, our recent research has discovered new ligands for c-MET in breast cancer. These newly identified ligands can potentially disrupt anticancer immunotherapy efforts by altering the immune cell composition within the tumor microenvironment, ultimately hindering the body's ability to combat cancer effectively. This discovery highlights the need for a deeper understanding of c-MET's role in breast cancer and its implications for immunotherapeutic approaches.

In our future team, we plan to jump much deeper into the c-MET mechanism and the functional roles of interactions of c-MET with its novel ligands. The results have yet to be published.